Imfinzi Interactions
There are 156 drugs known to interact with Imfinzi (durvalumab), along with 11 disease interactions. Of the total drug interactions, 42 are major, and 114 are moderate.
- View all 156 medications that may interact with Imfinzi
- View Imfinzi disease interactions (11)
Most frequently checked interactions
View interaction reports for Imfinzi (durvalumab) and the medicines listed below.
- albuterol
- amlodipine
- amoxicillin
- amoxicillin / clavulanate
- atorvastatin
- azithromycin
- biotin
- carboplatin
- Claritin (loratadine)
- dexamethasone
- doxycycline
- Eliquis (apixaban)
- famotidine
- Fish Oil (omega-3 polyunsaturated fatty acids)
- folic acid
- gabapentin
- levofloxacin
- lisinopril
- lorazepam
- metoprolol
- MiraLAX (polyethylene glycol 3350)
- nystatin
- ondansetron
- paclitaxel
- pantoprazole
- prednisone
- ProAir HFA (albuterol)
- prochlorperazine
- spironolactone
- Vitamin D3 (cholecalciferol)
Imfinzi disease interactions
There are 11 disease interactions with Imfinzi (durvalumab) which include:
- adrenal insufficiency
- colitis
- diabetes
- infections
- liver dysfunction
- renal dysfunction
- thyroid disorders
- Durvalumab – pneumonitis
- HSCT
- myasthenia gravis
- organ transplant
Report options
QR code containing a link to this page
More about Imfinzi (durvalumab)
- Imfinzi consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
